Table 5.
Cox regression analysis for risk of incident heart failure
| n = 130 | Model 1 | Model 2b | ||||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |||
| GAL4 | 1.49 | 1.23 | 1.81 | 4.9 × 10–5 | 1.26 | 1.03 | 1.54 | 0.024 |
| CTSD | 1.30 | 1.09 | 1.55 | 0.003 | 1.21 | 1.01 | 1.46 | 0.044 |
| FABP4 | 1.38 | 1.13 | 1.67 | 0.001 | 0.95 | 0.75 | 1.19 | 0.64 |
| PON3 | 0.80 | 0.69 | 0.93 | 0.003 | 0.95 | 0.81 | 1.12 | 0.57 |
| IGFBP2 | 1.01 | 0.84 | 1.22 | 0.91 | ||||
| CD163 | 1.11 | 0.92 | 1.33 | 0.28 | ||||
| PAI | 1.00 | 0.84 | 1.20 | 0.99 | ||||
CD163, scavenger receptor cysteine rich type 1 protein M130; CTSD, cathepsin D; FABP4, fatty acid‐binding protein 4; GAL4, galectin‐4; IGFBP2, insulin‐like growth factor‐binding protein 2; PAI, plasminogen activator inhibitor 1; PON3, paraoxonase‐3.
Values are hazard ratios (HRs) and 95% confidence intervals (95% CI) for incident heart failure. Model 1 is adjusted for age and sex. Model 2b is adjusted for age, sex, body mass index, systolic blood pressure, heart rate, anti‐hypertensive treatment, smoking, diabetes, prevalent atrial fibrillation, prevalent cardiovascular disease, cystatin C, and N‐terminal pro‐B‐type natriuretic peptide.